AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven

VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical(®), Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights * Q2 net revenue grew 18% year over year and 13% sequentially quarter-over-quarter to a record $21.7 million * Revenue growth driven by continued execution across the Company's key commercial portfolio, led by RECELL(®) and supported by increasing adoption of Cohealyx(®) and PermeaDerm(®), and complemented by consistent international revenue * Gross profit margin of 81.9%, an increase of 70 basis points year-over-year, reflecting the growth of RECELL alongside the expansion of the Company’s other product portfolio